ライフサイエンスコーパス: antithrombotic agent

1 natural products, including vitisinol D, an antithrombotic agent.

2 tamin K antagonist that is widely used as an antithrombotic agent.

3 and recombinant ADAMTS13 could be used as an antithrombotic agent.

4 advantages over unfractionated heparin as an antithrombotic agent.

5 would be much more potent than aspirin as an antithrombotic agent.

6 alue as an analgesic, anti-inflammatory, and antithrombotic agent.

7 otidase activities, would constitute a novel antithrombotic agent.

8 Aspirin is a widely used and effective antithrombotic agent.

9 accounting for the cAMP-directed activity of antithrombotic agents.

10 ere resistant to fibrinolysis or traditional antithrombotic agents.

11 es that are not controlled with conventional antithrombotic agents.

12 present a new and potentially safer class of antithrombotic agents.

13 f adverse effects associated with the use of antithrombotic agents.

14 ists thus represent a potential new class of antithrombotic agents.

15 atelet aggregation in vivo and are potential antithrombotic agents.

16 thrombogenesis and are potentially useful as antithrombotic agents.

17 ation cascade and for the development of new antithrombotic agents.

18 basis for the development of a new class of antithrombotic agents.

19 elective antagonists are sought as potential antithrombotic agents.

20 ssociated with less bleeding risk than other antithrombotic agents.

21 s that block these receptors might be useful antithrombotic agents.

22 to have significant therapeutic potential as antithrombotic agents.

23 nd to explore the role of newer, more potent antithrombotic agents.

24 use of specific inhibitors of GPIIb-IIIa as antithrombotic agents.

25 erol, smoking, physical activity, and use of antithrombotic agents.

26 We hypothesized that antithrombotic agents alter the release of angiogenesis

27 K-MB-/cTn+ were treated similarly with early antithrombotic agents and catheter-based interventions.

28 The use of antithrombotic agents and invasive procedures reduces is

29 ventional pathways, and can be attenuated by antithrombotic agents and loss-of-function proteins (as

30 (abciximab; ReoPro) has been approved as an antithrombotic agent, and other GP IIb/IIIa antagonists,

31 nts on the combination of antihypertensives, antithrombotic agents, and lipid-lowering drugs (relativ

32 ts with ACS, exclusive of revascularization, antithrombotic agents, and the use of high-intensity sta

33 ntly awaited, and the possibility that other antithrombotic agents--and combinations thereof--have a

34 Antithrombotic agents are an integral component of the m

35 ew devices, new thrombolytic agents, and new antithrombotic agents are continuously being introduced

36 Information on the efficacy of newer antithrombotic agents as adjunct to thrombolysis or prim

37 Utility of antithrombotic agents (ATAs) in these settings is restri

38 in could increase the therapeutic indices of antithrombotic agents by focusing on the destabilization

39 Antithrombotic agents can reduce the incidence of cerebr

40 Patients exposed to antithrombotic agents, compared with patients not expose

41 The cardiovascular and antithrombotic agent dipyridamole (DP) has potential the

42 g a potential clinical complication of novel antithrombotic agents directed toward the ITAM signaling

43 e of this study was to determine the optimal antithrombotic agent for heart failure patients with red

44 been used clinically as an anticoagulant and antithrombotic agent for over 60 years.

45 they show promise as a safe and efficacious antithrombotic agent for PCI.

46 Finally, LMWHs show promise as an antithrombotic agent for the treatment of ST-elevation m

47 Finally, ADAMTS13 could be an antithrombotic agent for thrombotic thrombocytopenic pur

48 of FXIa with a focus on discovering an acute antithrombotic agent for use in a hospital setting.

49 ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coro

50 Development of effective, yet safe, antithrombotic agents has been challenging because such

51 Although antithrombotic agents have potential in alleviating coca

52 nd avoidance of the concomitant use of other antithrombotic agents if feasible.

53 t, may have therapeutic potential as an oral antithrombotic agent in coronary and carotid artery thro

54 ng definitions, and has become the preferred antithrombotic agent in the setting of acute coronary sy

55 lopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous cor

56 including ACE inhibitors, beta-blockers, and antithrombotic agents in addition to lipid-lowering agen

57 bitors, such as CVS-1123, may be alternative antithrombotic agents in clinical settings in which hepa

58 follow-up of 3 months or longer that tested antithrombotic agents in patients who have nonvalvular a

59 may offer therapeutic advantages over other antithrombotic agents in terms of bleeding complications

60 Recent studies on antithrombotic agents in this setting have highlighted t

61 They also proved to be potent anticoagulant/antithrombotic agents in vivo on intravenous administrat

62 ule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer.

63 Antithrombotic agents increase risks of intracerebral ha

64 Our data suggest that the mechanism by which antithrombotic agents increase survival and decrease met

65 While currently available antithrombotic agents inhibit either platelet aggregatio

66 it was 3.5 (1.6 to 7.8), and for the use of antithrombotic agents it was 2.2 (1.0 to 4.8).

67 rinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk.

68 racerebral hemorrhage attends the use of all antithrombotic agents, most notably plasminogen activato

69 tially replace unfractionated heparin as the antithrombotic agent of choice across the spectrum of AC

70 men) received at least 1 prescription for an antithrombotic agent over the study period.

71 rrelations shed light on mechanisms by which antithrombotic agents prevent stroke.

72 IA-H, treatment with bapineuzumab and use of antithrombotic agents provides additional support for th

73 even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogr

74 The currently available antithrombotic agents target the interaction of platelet

75 Antithrombotic agents that are inhibitors of factor XIa

76 sly demonstrated in a series of searches for antithrombotic agents that diadenosine 5',5"'-P1,P4-tetr

77 ds offer a new platform for developing novel antithrombotic agents that target procoagulant anionic p

78 and safe alternative to currently available antithrombotic agents to restore vessel patency after ar

79 ines, glycoprotein IIb/IIIa inhibitors), and antithrombotic agents (unfractionated heparin and low-mo

80 son-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-ye

81 Thus, a new antithrombotic agent was developed for platelet thrombus

82 The potential of 3 as antithrombotic agent was supported by its ability to inh

83 Antithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory proper